BioMimetic Therapeutics, which is developing biologically active drug-device combination products to heal skeletal diseases and injuries, priced its offering of 4.6 million shares at $8, a 33% discount to its proposed $11-$13 range. Deutsche Bank and Pacific Growth Equities were joint book-running managers for this IPO. The stock is expected to commence trading on the NASDAQ under the ticker symbol "BMTI" on Friday.
